Observational studyInternal and emergency medicine2026
Comparison of profiles of biomarkers of potential harm among healthy adults who used heated tobacco products, smoked combustible cigarettes, or who had never smoked: a cross-sectional, observational study.
Observational study in Internal and emergency medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Respiratory function, functional capacity, dyspnea, and sleep quality in young adults using the IQOS heated tobacco product: a matched cross-sectional study.Internal and emergency medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This cross-sectional observational study assessed exposure to a selected combustible cigarette (CC) smoke constituent and biomarkers of potential harm (BoPH) in healthy adults who exclusively used a heated tobacco product (direct heating tobacco system, platform 3, generation 3, version a [DT3.0a] group, n = 304), smoked CC (CC group, n = 102), or had never smoked CC (NS group, n = 102), to evaluate biomarker profiles relevant to health risks associated with smoking. Relative to the CC group, exposure to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone was 39.1% lower in the DT3.0a group (p < 0.01), and several BoPH were lower in the DT3.0a group, including 2,3-dinor-thromboxane-B2 (- 19.4%, p = 0.04), 11-dehydrothromboxane-B2 (- 10.2%, p = 0.25), 8-epi-prostaglandin-F2α (- 7.2%, p = 0.42), and white blood cell count (- 11.6%, p = 0.05). Relative to the CC group, high-density lipoprotein cholesterol was 32.0% higher in the DT3.0a group (p < 0.01) with pulmonary function parameters also being higher, although the differences were not statistically significant. For these biomarkers, the NS group exhibited trends similar to those observed in the DT3.0a group. In contrast to previous findings, soluble intercellular adhesion molecule-1 levels were similar between the CC and NS groups and highest in the DT3.0a group, suggesting that further assessments may be more appropriate in the context of change in values. Except for this point, the DT3.0a group showed BoPH profiles trending in the direction toward those of the NS group, suggesting that the health risks associated with smoking are potentially lower in DT3.0a use compared to CC smoking.Trial Registration : Prior to the recruitment, the study was registered at the UMIN Clinical Trials Registry on December 27, 2022(UMIN000049840).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.